Enlaza launches with $61M, aims to take covalency into protein drugs
Covalent small molecule drug development has seen a bit of a renaissance in recent years. But a new San Diego-based biotech wants to take covalency one step further — into protein drugs.
Enlaza Therapeutics launched out of stealth Thursday morning with $61 million in funding. The round was led by Avalon Ventures, followed by Lightspeed Venture Partners, Frazier Life Sciences and Samsara BioCapital.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,400+ biopharma pros reading Endpoints daily — and it's free.